ADA Annual Meeting 2010
- Exenatide Combined with Basal Insulin Improves Glycemic Control with Favorable Non-Glycemic Effects
Exenatide and basal insulin are commonly used to advance treatment of type 2 diabetes. While currently not indicated for combination treatment in type 2 diabetes mellitus (T2DM), the effects of combining exenatide with insulin therapy in patients with T2DM are being explored.
Read More- Comments(0)
- Clinical Trial Data Reported for an Investigational Ultra-Rapid-Acting Insulin
Faster-acting insulins are needed to more closely mimic physiological insulin secretion; the development of ultra-rapid-acting insulins is considered a key barrier to the development of a fully automated, closed-loop insulin delivery system (ie, artificial pancreas). This report summarizes an oral abstract presented on a monomeric, ultra-rapid-acting human insulin at the American Diabetes Association 70th Annual Scientific Sessions on June 25, 2010.
Read More- Comments(0)
- Implications of U.S. Health Care Reform on the Care and Prevention of Diabetes
A panel of experts discussed the potential impact of U.S. health care reform for patients with diabetes. The focus of this program was the recently enacted U.S. health care reform bill, the Patient Protection and Affordable Care Act. In the course of the symposium, the expert speakers
• Outlined the need for improved access to evidence-based health care for patients with diabetes• Summarized anticipated gains and pitfalls for patients with diabetes under the recent health care reform• Described the role of communities in improving health care outcomes• Provided examples of community-based programs that may provide efficient and cost-effective means to achieve health care reform goals.Read More- Comments(0)
- Phase 2 Clinical Trial Data Reported for Insulin Degludec, an Investigational Ultra-Long-Acting Basal Insulin Analog
Current insulin therapy is not a perfect replacement for endogenous insulin. Recent research is directed toward resolving the lack of predictability of insulin action within and between individuals, maintaining long-lasting peakless action in basal insulins, and increasing the speed of rapid-acting insulins. A total of 7 oral abstracts presented at the American Diabetes Association 70th Annual Scientific Sessions on June 25, 2010 featured data from clinical trials of these new insulins. This report summarizes oral abstracts presented on insulin degludec, a new ultra-long-acting basal insulin analog.
Read More- Comments(0)
- Welcome to ADA 2010
Welcome to conference coverage of the American Diabetes Association 70th Annual Scientific Sessions conducted in Orlando, Florida on June 25-29, 2010. For those involved in diabetes research or the delivery of diabetes care and services, this is the world's largest diabetes meeting. If you were fortunate enough to attend the meeting, you heard firsthand the educational lectures from global diabetes experts and the latest in cutting-edge science and research. If you weren't able to attend in person, these conference reports will provide you with highlights of important, cutting-edge, and clinically relevant information presented at the meeting.
Read More- Comments(0)